treatment | Page 61 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

treatment

Deferiprone

Deferiprone is in a class of medications called iron chelators. It works by attaching to iron in the body so that it can be excreted (removed from the body).

Deferasirox

It comes in a tablet form which is dissolved in juice or water and taken by mouth. Iron build-up can occur in patients who get a lot of red blood cell transfusions. Deferasirox binds with the iron in the body and is removed by the kidneys.

Decitabine

It works by reducing the amount of methylation in the body. Methylation is a process that acts like a switch to turn off or “silence” genes in certain cells. When these genes (called tumor suppressor genes) are turned off, MDS cells and cancer cells can grow freely. Decitabine is approved by the U.S. Food and Drug Administration (FDA) for treating all MDS subtypes, though it is used most commonly to treat higher-risk MDS.

Daclizumab

It is approved by the U.S. Food and Drug Administration (FDA) for use in transplant patients to reduce the chance of organ rejection. Currently, researchers are studying daclizumab for treating

Azacitidine

It works by reducing the amount of methylation in the body. Methylation is a process that acts like a switch to turn off or “silence” genes in certain cells. When these genes (called tumor suppressor genes) are turned off, MDS cells and cancer cells can grow freely. Azacitidine is approved by the U.S. Food and Drug Administration (FDA) for treating all

Arsenic Trioxide

It is approved by the U.S. Food and Drug Administration (FDA) for treating acute promylocitic leukemia (APL). Currently, researchers are studying arsenic trioxide, as a single agent or in combination with other medicines, for treating